Clinicopathological Diagnosis and Differential Criteria of Thrombocythemias in Various Myeloproliferative Disorders by Histopathology, Histochemistry and Immunostaining from Bone Marrow Biopsies

References

• Michiels J. J. The myeloproliferative disorders. A historical appraisal and personal experiences. Leukemia Lymphoma 1996; 22(Suppl 1)1–14
   PubMed Web of Science ®Google Scholar
• Ravandi‐Kashani F., Schafer A. I. Microvascular disturbances, thrombosis and bleeding in thrombocythemia. Semin. Thromb. Hemostas. 1997; 23: 479–86
   PubMed Web of Science ®Google Scholar
• Wehmeier A., Daum I., Jamin H., Schneider W. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients. Ann. Hematol. 1991; 63: 101–6
   PubMed Web of Science ®Google Scholar
• Michiels J. J., van Genderen P. J. J., Lindemans J., van Vliet H. H.D. M. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leukemia Lymphoma 1996; 22(Suppl. 1)47–56
   PubMed Web of Science ®Google Scholar
• Finazzi G., Budde U., Michiels J. J. Bleeding time and platelet function in essential thrombocythemia and other myeloproliferative syndromes. Leukemia Lymphoma 1996; 22(Suppl. 1)71–8
   PubMed Web of Science ®Google Scholar
• Mason J. E., DeVita V. T., Canellos G. P. Thrombocytosis in chronic granulocytic leukemia: incidence and clinical significance. Blood 1974; 44: 483–487
   PubMed Web of Science ®Google Scholar
• Burkhardt R. Bone marrow in megakaryocyte disorders. Hematol. Oncol. Clin. N. Am. 1988; 2: 695–733
   PubMed Web of Science ®Google Scholar
• Thiele J., Schneider G., Hoeppner B., Wienhold S., Zank‐ovich R., Fischer R. Histomorphometry of bone marrow biopsies in chronic myeloproliferative disorders with associated thrombocytosis‐features of significance for the diagnosis of primary (essential) thrombocythemia. Virchows Arch. A. Pathol. Anat. 1988; 413: 407–17
   Google Scholar
• Buss D. H., O'Conner M. L., Woodruff R. D., Richards F., II, Brockschmidt J. K. Bone marrow and peripheral blood findings in patients with extreme thrombocytosis. Arch. Pathol. Lab. Med. 1991; 115: 475–80
   PubMed Web of Science ®Google Scholar
• Buhr T., Georgii A., Schuppan O., Amor A., Kloutsi V. Histologic findings in bone marrow biopsies of patients with thrombocythemic cell counts. Ann. Hematol 1992; 64: 286–91
   PubMed Web of Science ®Google Scholar
• Burkhardt R., Bartl R., Jaeger K., Frisch B., Kettner G., Mahl G., et al. Chronic myeloproliferative disorders (CMPD). Path. Res. Pract. 1984; 179: 131–86
   PubMed Web of Science ®Google Scholar
• Georgii A., Vykoupil K. F., Buhr T., Choritz H., Döhler U., Kaloutsi V., et al. Chronic myeloproliferative disorders in bone marrow biopsies. Path. Res. Pract. 1990; 186: 3–27
   PubMed Web of Science ®Google Scholar
• Dickstein J. I., Vardiman J. W. Issues in the pathology and diagnosis of the chronic myeloproliferative disorders and the myelodysplastic syndromes. Am. J. Clin. Pathol. 1993; 99: 513–25
   PubMed Web of Science ®Google Scholar
• Bartl R., Frisch B., Wilmanns W. Potential of bone marrow biopsy in chronic myeloproliferative disorders (MPD). Eur. J. Haematol. 1993; 50: 41–52
   PubMed Web of Science ®Google Scholar
• Iland H. J., Laszlo J., Peterson P., Murphy S., Brière J., Weinfeld A., et al. Essential thrombocythemia: clinical and laboratory characteristics at presentation. Trans. Assoc. Am. Phys. 1983; 96: 165–74
   PubMedGoogle Scholar
• Murphy S., Iland H., Rosenthal D., Laszlo J. Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group. Semin, Hematol. 1986; 23: 177–82
   PubMed Web of Science ®Google Scholar
• Iland H. J., Laszlo J., Case D. C., Murphy S., Reichert T. A., Tso C. Y., et al. Differentiation between essential thrombocythemia and polycythemia vera with marked thrombocytosis. Am. J. Hematol. 1987; 25: 191–201
   PubMed Web of Science ®Google Scholar
• Thiele J., Kvasnicka H. M., Werden C., Zankovich R., Diehl V., Fischer R. Idiopathic primary osteo‐myelofibrosis: a clinico‐pathological study on 208 patients with special emphasis on evolution of disease features, differentiation from essential thrombocythemia and variables of prognostic impact. Leukemia Lymphoma 1996; 22: 303–17
   PubMed Web of Science ®Google Scholar
• Gatter K. C., Cordell J. L., Turley H., Heryet A., Kiefer N., Anstee D. J., et al. The immunohistological detection of platelet, megakaryocytes and thrombi in routinely processed specimens. Histopathology 1988; 13: 257–67
   PubMed Web of Science ®Google Scholar
• Mahmood T., Robinson W. A., Hamstra R. D., Wallner S. F. Macrocytic anemia, thrombocytosis and nonlob‐ulated megakaryocytes. The 5q‐syndrome, a distinct entity. Am. J. Med. 1979; 66: 946–955
   PubMed Web of Science ®Google Scholar
• Michiels J. J. Diagnostic criteria of the myeloproliferative disorders (MPD): essential thrombocythemia, poly‐cythaemia vera and chronic megakaryocytic granulocytic metaplasia. Neth. J. Med. 1997; 51: 57–64
   PubMed Web of Science ®Google Scholar
• Michiels J. J., Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin. Thromb. Hemostas. 1997; 23: 339–47
   PubMed Web of Science ®Google Scholar
• Mathew P., Terrefi A., Dewald G. W., Soldberg S. L., Su J., Hoagland H. C., et al. The 5q‐syndrome: a single‐institution study of 43 consecutive patients. Blood 1993; 81: 1040–5
   PubMed Web of Science ®Google Scholar
• Thiele J., Kvasnicka H. M., Titius B. R., Parpert U., Nebel R., Zankovich R., et al. Histological features of prognostic significance in CML—an immunohistochemical and morphometric study (multivariate regression analysis) on trephine biopsies of the bone marrow. Ann. Hematol. 1993; 66: 261–302
   PubMed Web of Science ®Google Scholar
• Kaplan E. L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc 1958; 53: 457–81
   Web of Science ®Google Scholar
• Hakama M., Hakulinen T. Estimating the expectation of life in cancer survival studies with incomplete follow‐up informations. J. Chron. Dis. 1977; 30: 585–97
   PubMedGoogle Scholar
• Hakulinen T. Cancer survival corrected for heterogeneity in patient withdrawal. Biometrics 1982; 32: 933–42
   Web of Science ®Google Scholar
• Thiele J., Fischer R. Megakaryocytopoiesis in haematological disorders: diagnostic features of bone marrow biopsies. Virchows Archiv A. Pathol. Anat. 1991; 418: 87–97
   Google Scholar
• Bellucci S., Janvier M., Tobelem G., Flandrin G., Charpak Y., Berger R., et al. Essential thrombocythemias. Clinical evolutionary and biological data. Cancer 1986; 58: 2440–7
   PubMed Web of Science ®Google Scholar
• Hehlmann R., Jahn M., Baumann B., Köpcke W. Essential thrombocythemia. Clinical characteristics and course of 61 cases. Cancer 1988; 61: 2487–96
   PubMed Web of Science ®Google Scholar
• Fenaux P., Simon M., Caulier M. T., Lai J. L., Goudem‐mand J., Bauters F. Clinical course of essential thrombocythemia in 147 cases. Cancer 1990; 66: 549–56
   PubMed Web of Science ®Google Scholar
• Kutti J., Wadenvik H. Diagnostic and differential criteria of essential thrombocythemia and reactive thrombocytosis. Leukemia Lymphoma 1996; 22: 41–5
   PubMed Web of Science ®Google Scholar
• Thiele J., Zankovich R., Steinberg T., Kremer B., Fischer R., Diehl V. Primary (essential) thrombocythemia versus initial (hyperplastic)stages of agnogenic myeloid metaplasia with thrombocytosis—A critical evaluation of clinical and histomorphological data. Acta Haemat. 1989; 81: 192–202
   PubMed Web of Science ®Google Scholar
• Dickstein J. I., Vardiman J. W. Hematopathologic findings in the myeloproliferative disorders. Semin. Oncol. 1995; 22: 355–73
   PubMed Web of Science ®Google Scholar
• Bilgrami S., Greenberg B. R. Polycythemia rubra vera. Semin. Oncol. 1995; 22: 307–26
   PubMed Web of Science ®Google Scholar
• Ellis J. T., Peterson P., Geller S. A., Rappaport H. Studies of the bone marrow in polycythemia vera and the evolution of myelofibrosis and second hematologic malignancies. Semin. Hematol. 1986; 23: 144–55
   PubMed Web of Science ®Google Scholar
• Lemoine F., Najman A., Baillou C., Stachowiak J., Boffa G., Aegerter P., et al. A prospective study of the value of bone marrow erythroid progenitor cultures in polycythemia. Blood 1986; 68: 996–1002
   PubMed Web of Science ®Google Scholar
• Thiele J., Zankovich R., Schneider G., Kremer B., Fischer R., Diehl V. Primary (essential) thrombocythemia versus polycythemia vera rubra. A histomorpho‐metric analysis of bone marrow features in trephine biopsies. Analyt. Quant. Cytol. Histol. 1988; 10: 375–82
   PubMed Web of Science ®Google Scholar
• Lengfelder E., Hochhaus A., Kronawitter U., Höche D., Queisser W., Jahn‐Eder M., et al. Should a platelet limit of 600×109/1 be used as a diagnostic criterion in essential thrombocythaemia? An analysis of the natural course including early stages. Br. J. Haematol. 1998; 100: 5–23
   Web of Science ®Google Scholar
• Kaloutsi V., Fritsch R. S., Buhr R., Restrepo‐Specht I., Widjaja W., Georgii A. Megakaryocytes in chronic myeloproliferative disorders: numerical density correlated between different entities. Virchows Arch. A. Pathol. Anat. 1991; 418: 493–7
   Google Scholar
• Nafe R., Georgii A., Kaloutsi V., Fritsch R. S., Choritz H. Planimetric analysis of megakaryocytes in the four main groups of chronic myeloproliferative disorders. Virchows Archiv B Cell. Pathol. 1991; 61: 111–6
   Google Scholar
• Buhr T., Georgii A., Choritz H. Myelofibrosis in chronic myeloproliferative disorders. Incidence among subtypes according to the Hannover Classification. Path. Res. Pract. 1993; 189: 121–132
   PubMed Web of Science ®Google Scholar
• Thiele J., Chen Y. S., Kvasnicka H. M., Diehl V., Fischer R. Evolution of fibro‐osteosclerotic bone marrow lesions in primary (idiopathic) osteomyelofibrosis‐a histomorphometric study on sequential trephine biopsies. Leukemia Lymphoma 1994; 14: 163–169
   PubMed Web of Science ®Google Scholar
• Georgii A., Buhr T., Buesche G., Kreft A., Choritz H. Classification and staging of Ph‐negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leukemia Lymphoma 1996; 22(Suppl. 1)15–29
   PubMed Web of Science ®Google Scholar
• Wolf B. C., Neiman R. S. Myelofibrosis with myeloid metaplasia: pathophysiologic implications of the correlation between bone marrow changes and progression of splenomegaly. Blood 1985; 65: 803–9
   PubMed Web of Science ®Google Scholar
• Rozman C., Giralt M., Feliu R., Rubio D., Cortes M. T. Life expectancy of patients with chronic nonleuke‐mic myeloproliferative disorders. Cancer 1991; 67: 2658–63
   PubMed Web of Science ®Google Scholar
• Anger B., Seidler R., Haug U., Popp C., Heimpel H. Idiopathic myelofibrosis: a retrospective study of 103 patients. Haematologica 1990; 75: 228–34
   PubMedGoogle Scholar
• Visani G., Finelli C., Castelli U., Petti M. C., Ricci R., Vianelli N., et al. Myelofibrosis with myeloid metaplasia, clinical and haematological parameters predicting survival in a series of 133 patients. Br. J. Haematol 1990; 75: 4–9
   PubMed Web of Science ®Google Scholar
• Dupriez B., Morel P., Demory J. L., Lai J. L., Simon M., Plantier I., et al. Prognostic factors on agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. Blood 1996; 88: 1013–18
   PubMed Web of Science ®Google Scholar
• Kvasnicka H. M., Thiele J., Werden C., Zankovich R., Diehl V., Fischer R. Prognostic factors in idiopathic (primary) osteomyelofibrosis. Cancer 1997; 80: 708–19
   PubMed Web of Science ®Google Scholar